Avastin shares the same anti-VEGF mechanism of action as Novartis’ Lucentis (ranibizumab), which has been approved for AMD for more than a decade, but works out far cheaper at around €82 per ...

and compared Eylea versus Novartis' rival treatment Lucentis, and Roche's Avastin. The trial came about because of extensive off-label prescribing of Avastin against eye diseases such as age ...